|
Report Date : |
25.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
SHINPOONG PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
434-4, Mongnae-dong, Danwon-gu, Ansan-si, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2012 |
|
|
|
|
Date of Incorporation : |
23.07.1986 |
|
|
|
|
Com. Reg. No.: |
134-81-03819 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Manufacture of Finished Medicaments |
|
|
|
|
No. of Employees : |
860 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made on
e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company
Name |
SHINPOONG PHARMACEUTICAL
CO., LTD. (Korean Company
Name : “신풍제약(주)”) |
|
Registered Address |
434-4, Mongnae-dong, Danwon-gu, Ansan-si, |
|
Zip Code |
425-100 |
|
Tel |
+82-31-491-6191~2 |
|
Fax |
+82-31-491-6193 |
|
E-mail |
|
|
Website |
|
|
Trading Address |
748-31, Yeoksam-dong, Gangnam-gu, |
|
Tel |
+82-2-2189-3400 |
|
Fax |
+82-2-2189-3439 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Finished Medicaments |
|
Main Business |
Anti-inflammatory Analgesic, Antibiotics,
Anti-cancer Medicine, Anthelmintics, Digestive |
|
Established (mm/dd/yyyy) |
07/23/1986 |
The Subject owns
the premises of registered HQ address/Factory and the trading address.
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antibiotics(51101500) |
|
Sell |
Nonsteroidal anti inflammatory drugs
NSAIDs(51142100) |
|
Sell |
Drugs used for respiratory tract
disorders(51161700) |
|
Sell |
Urinary anti infectives and analgesics(51102200) |
|
Sell |
Antifungal drugs(51101800) |
|
Sell |
Vitamin supplements(51191905) |
|
Sell |
Drugs used for gallbladder disease(51172000) |
|
Sell |
Anthelmintics and other antiparasitics(51101700) |
|
Name |
Kim Byung-Hwa |
|
Date of Birth |
01/26/1944 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
20,118,385,000 |
||||||||||||||||||||||||
|
Employees |
860 |
||||||||||||||||||||||||
|
Formation |
Listed Company ( |
||||||||||||||||||||||||
|
Bank Details |
Korea Exchange Bank-Yeoksam Dong Branch Shinhan Bank Korea Development Bank |
||||||||||||||||||||||||
|
Corporate Registered No. |
130111-0011815 |
||||||||||||||||||||||||
|
Business Registered No. |
134-81-03819 |
||||||||||||||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 950923 |
||||||||||||||||||||||||
|
Shareholder Position |
|
||||||||||||||||||||||||
|
Company History |
2008 Completed PYRAMAX (new anti-malarial Agent)
dedicated factory in compliance with EU GMP in Ansan city. 2006 Awarded "Medicines for Malaria
Venture's (MMV) Project of the Year" for 2005. 2005 Awarded "Twenty Million US dollar
2004 Synthesized "Glimepiride". 2003 Synthesized "Cefmetazole
Sodium". 2002 Completed KGMP penicillin factory in
Ansan city. 2002 Established PHIL. SHINPOONG PHARMA
INC. in 2001 Synthesized "Fosfomycin
Sodium" (antibiotic). 1999 Synthesized "Aceclofenac"
(NSAID). 1998 Synthesized "Tiropramide"
(antispasmodic agent). 1998 Synthesized "Doxifluridine"
(anticancer drug) for the second time in the world, the first time in 1997 Synthesized "Cefazedone
sodium" (antibiotic). 1997 Synthesized "Loxoprofen" (NSAID)
for the second time in the world. 1996 Established SHINPOONG DAEWOO PHARMA
CO., LTD. in 1995 Synthesized "Ceftizoxime"
(antibiotic). 1995 Established TIANJIN SHINPOONG PHARM.
CO., LTD. in 1992 Awarded "Ten Million US dollar 1988 Established GENERAL MEDICINES CO.,
LTD. in 07/23/1986 Incorporated as SHIN POONG
PHARM. CO., LTD. 1984 Conferred the Order of Civil Merit
MOK-RYUN Medal for the first time in Korean Pharmaceutical industry history. 1984 Completed the KGMP factory in Ansan
city. 1983 Synthesized
"Praziquantel"(anthelmintic) for the second time in the world. 1975 Synthesized
"Mebendazole"(anthelmintic). 1962 Established as SHIN POONG
PHARMACEUTICAL CO. |
||||||||||||||||||||||||
|
|
|
|
Job Description |
Title |
Name |
Nationality |
Date of Birth |
Education |
|
President & CEO |
Mr. |
Kim Chang-Kyun |
Korean |
1956.03.03 |
|
|
Sr. Executive Director |
Mr. |
Lee Sung-Tae |
Korean |
1937.12.12 |
|
|
Outside Director |
Mr. |
Cho Hyun-Je |
Korean |
1936.09.13 |
|
|
Outside Director |
Mr. |
Kim Hak-Soo |
Korean |
1949.01.06 |
- |
|
Auditor |
Mr. |
Yoon Soo-Duck |
Korean |
1938.02.25 |
- |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
47,072,854,567 |
371,696,318,612 |
3,477,133,053 |
|
|
(*)2011 |
224,915,147,482 |
370,849,235,191 |
24,417,807,606 |
|
(*)2010 |
224,719,180,623 |
361,962,379,960 |
20,862,584,686 |
|
2009 |
207,944,403,845 |
292,224,036,233 |
18,861,690,865 |
|
2008 |
181,354,253,481 |
252,887,164,135 |
10,190,277,455 |
|
2007 |
161,393,076,297 |
212,248,883,926 |
8,809,137,852 |
|
2006 |
154,979,986,643 |
196,130,857,044 |
21,899,546,370 |
|
2005 |
150,027,107,159 |
184,599,750,889 |
11,831,931,590 |
|
2004 |
138,749,317,287 |
169,201,648,928 |
1,387,072,281 |
(*) Figures are based
on the K-IFRS Accounting System.
|
Authorized Capital(KRW) |
40,000,000,000 |
|
Paid-Up Capital(KRW) |
20,118,385,000 |
|
Total Issues Shares |
4,023,677(Common:3,803,677, Preferable:220,000) |
Balance
Sheet
|
|||
|
Unit : Korean Won |
01/01/2012~03/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Total Assets |
371,696,318,612 |
370,849,235,191 |
361,962,379,960 |
|
Current Assets |
188,340,357,783 |
194,457,037,701 |
203,017,576,372 |
|
Cash & Cash
Equivalents |
939,967,157 |
2,860,748,135 |
2,210,726,090 |
|
Current Financial
Instruments |
20,000,000 |
1,100,000,000 |
2,660,000,000 |
|
Trade Receivables
& Other Receivables |
140,233,584,302 |
148,796,453,285 |
155,213,448,699 |
|
Current Financial
Instruments |
2,498,165,105 |
1,977,894,779 |
3,088,254,643 |
|
Current Non-Financial
Instruments |
895,189,258 |
877,722,105 |
861,550,449 |
|
Inventories |
43,753,451,961 |
38,844,219,397 |
38,983,596,491 |
|
Non-Current Assets |
183,355,960,829 |
176,392,197,490 |
158,944,803,588 |
|
Non-Current Financial
Instruments |
1,340,000,000 |
1,070,000,000 |
400,000,000 |
|
Marketable Financial Instruments |
69,726,243 |
69,626,243 |
69,526,243 |
|
Other Non-Current
Financial Instruments |
1,886,600,870 |
1,891,670,870 |
1,800,670,870 |
|
Investment_Related
Companies |
13,708,563,044 |
13,708,563,044 |
11,538,218,949 |
|
Tangibles |
152,476,171,832 |
146,606,212,420 |
138,736,002,462 |
|
Intangibles |
10,663,491,693 |
9,656,875,736 |
2,806,846,876 |
|
Deferred Income Tax
Assets |
3,211,407,147 |
3,389,249,177 |
3,593,538,188 |
|
Total Liabilities |
196,453,992,507 |
196,889,165,489 |
209,712,242,686 |
|
Current Liabilities |
154,991,159,759 |
152,778,202,571 |
164,246,153,592 |
|
Trade Payables &
Other Payables |
27,514,507,428 |
22,046,475,451 |
27,771,709,556 |
|
Short-Term Borrowings |
111,062,534,516 |
118,033,100,247 |
120,379,388,026 |
|
Other Current Financial
Debts |
12,352,843,545 |
8,300,725,688 |
7,458,064,220 |
|
Other Current
Non-Financial Debts |
1,972,969,468 |
2,961,631,261 |
3,786,234,157 |
|
Deferred Income Tax
Credit |
2,088,304,802 |
1,436,269,924 |
4,850,757,633 |
|
Non-Current
Liabilities |
41,462,832,748 |
44,110,962,918 |
45,466,089,094 |
|
Long-Term Borrowings |
17,699,175,393 |
19,828,064,818 |
20,245,721,176 |
|
Other Non-Current
Financial Debts |
213,940,869 |
200,450,380 |
129,747,600 |
|
Provision for
Severance & Retirement |
17,373,158,370 |
17,185,289,017 |
16,538,575,728 |
|
Provision for
Severance & Retirement |
657,698,847 |
631,800,193 |
514,206,260 |
|
Other Non-Current
Provisions |
5,518,859,269 |
6,265,358,510 |
8,037,838,330 |
|
Capital Stock |
20,644,385,000 |
20,644,385,000 |
20,118,385,000 |
|
Capital Surplus |
21,740,074,715 |
21,740,074,715 |
21,741,390,315 |
|
Others |
-10,827,570,961 |
-11,549,270,961 |
-11,521,624,171 |
|
Profit Surplus |
143,685,437,351 |
143,124,880,948 |
121,911,986,130 |
|
Total Equity |
175,242,326,105 |
173,960,069,702 |
152,250,137,274 |
|
Liab. &
Shareholder’s Equity |
371,696,318,612 |
370,849,235,191 |
361,962,379,960 |
Income
Statement
|
|||
|
Unit : Korean Won |
01/01/2012~03/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Sales |
47,072,854,567 |
224,915,147,482 |
224,719,180,623 |
|
Cost of Sold Goods |
26,423,157,384 |
124,859,589,027 |
118,074,958,831 |
|
Gross Profit |
20,649,697,183 |
100,055,558,455 |
106,644,221,792 |
|
Selling & Admin.
Expenses |
14,512,031,652 |
62,280,307,135 |
64,640,510,381 |
|
Other Operating
Income |
109,676,975 |
1,642,461,304 |
1,611,888,423 |
|
Other Operating
Expenses |
235,045,455 |
796,362,528 |
1,246,697,502 |
|
Operating Income |
6,012,297,051 |
38,621,350,096 |
42,368,902,332 |
|
Finance Income |
304,191,417 |
264,939,470 |
766,544,119 |
|
Finance Expenses |
1,997,770,867 |
8,362,182,793 |
7,398,944,899 |
|
Income Before Taxes |
4,318,717,601 |
30,524,106,773 |
35,736,501,552 |
|
Income Taxes Expenses |
841,584,548 |
6,106,299,167 |
14,873,916,866 |
|
Net Income |
3,477,133,053 |
24,417,807,606 |
20,862,584,686 |
Cash
Flows
|
|||
|
Unit : Korean Won |
01/01/2012~03/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Operating
Activities Cash Flows |
14,828,211,355 |
29,243,561,818 |
2,144,155,735 |
|
Cash Flows from Operating |
16,676,622,516 |
45,367,725,054 |
27,918,889,670 |
|
Interests Received |
83,626,784 |
156,398,323 |
23,488,093 |
|
Interests Paid |
-1,920,402,461 |
-7,923,683,115 |
-7,282,686,507 |
|
Dividends Received |
72,156 |
881,128,844 |
730,721,739 |
|
Income Taxes |
-11,707,640 |
-9,238,007,288 |
-19,246,257,260 |
|
Cash Flows from Investing |
-7,895,681,817 |
-23,405,465,939 |
-16,342,478,549 |
|
Cash Flows from Financing |
-8,846,135,814 |
-5,195,595,323 |
13,359,881,018 |
|
Increase/Decrease in Cash |
-7,174,702 |
7,521,489 |
6,147,586 |
|
Cash at the Beginning of Year |
2,860,748,135 |
2,210,726,090 |
3,043,020,300 |
|
Cash at the End of Year |
939,967,157 |
2,860,748,135 |
2,210,726,090 |
|
Main Products & Services |
Antibiotics Analgesic, Anti-inflammatory, Antipyretics Anti-inflammatory Enzyme Corticosteroids Antacids Digestives and antiulcer agents Antispasmodics Sedative agent Geriatric agents and Vitamins Ageuts Drugy, Calcium Supplement Prophylaxic and therapy of liver disease Amino Acids Gingival agents Antitussives and Expectorants Antihistamines Thrombolytics Antihypertensives Hemostatics Antidiabetics Cerebral Circulation and Metabolism Amelioraters For disk and peripheral Neuropathies Ophthalmic Agents Otorthinologic Agents Otorhinologic agents Anti-Fungal Agents Antimycotics Topical Dermatic Prepar Anthelmintics Remedy for tropical diseases |
|
Competitors |
JEIL PHARMACEUTICAL CO., LTD.(110111-0026652) 745-5, BANPO 1-DONG, SEOCHO-GU, TEL:+82-2-549-7451
FAX:+82-2-549-7478 BORYUNG PHARM CO., LTD.(110111-0012560) 15TH FL., BORYEONG BLDG., 66-21, WONNAM-DONG, JONGNO-GU, TEL:+82-2-708-8000
FAX:+82-2-742-6362 KWANGDONG PHARMACEUTICAL CO., LTD(110111-0152134) 4TH FL., GASAN BLDG., 1577-4, SEOCHO
3-DONG, SEOCHO-GU, TEL:+82-2-6006-7777 FAX:+82-2-6006-702 |
(Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
(45.0% held by the subject company) SHINPOONG DAEWOO PHARMA. CO., LTD.( (94.1% held by the subject company) GENERAL MEDICINES CO., LTD.( (33.3% held by the subject company) PHILIPPINE SHINPOONG PHRAMA CO., LTD. (80.0% held by the subject company) |
|
Subsidiary |
SHINPOONG DAEWOO PHARMA. CO., LTD.( (96.4% held by the subject company) |
|
Cooperative |
-Insured Company DONGBU INSURANCE CO., LTD.(110111-0095285) |
(Activity &
Markets)
|
Sales/ Unit :Mil KRW |
03/2012 |
2011 |
2010 |
|
Export |
4,481 |
4,444 |
17,698 |
|
Domestic |
42,592 |
52,828 |
207,217 |
|
Total |
47,073 |
57,272 |
224,915 |
The Subject deals
with the companies in
|
Case No. |
Court |
Plaintiff(s)/
Creditor(s)/ Applicant(s) |
Defendant(s)/
Debtor(s)/ Respondent(s) |
Cause |
Amount (Million KRW) |
Status |
|
|
Civil Court in |
The Subject Company |
CODUPHA( |
Claim for Receivables |
$1,160,000 |
Filed as of 05/2004 |
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.56.99 |
|
|
1 |
Rs.88.97 |
|
Euro |
1 |
Rs.71.57 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.